Financial conflicts of interest among oncologist authors of reports of clinical drug trials
Cet article évalue la présence et l'importance des conflits d'intérêt et des relations financières existant entre les laboratoires pharmaceutiques et les oncologues ayant mené des essais cliniques sur des médicaments autorisés par la Food and Drug Administration
In medical research, a financial conflict of interest (FCOI) may affect the conduct and reporting of clinical trials.1 The presence of FCOIs in clinical trials of oncology drugs that receive US Food and Drug Administration (FDA) approval is of particular concern, because these trials may change the trajectory of cancer care. These trials also generate high–impact factor publications, prestige for authors, revenue for the pharmaceutical companies, and newsworthy headlines. The primary objective of this investigation was to quantify the prevalence and magnitude of industry-oncologist financial relationships in trials of oncology drugs that received FDA approval. The secondary objective was to identify the proportion of undisclosed FCOIs among oncologist authors.